---
title: Tufts CSDD Impact Report | CluePoints
description: Discover how Tufts CSDD conducted this research and evaluated the responses to determine why the adoption of RBQM remains limited in this on-demand report.
---

# Impact Report

### Tufts Center for the Study of Drug Development Impact Report: Analysis & Insight Into Critical Drug Development Issues

### Approximately half of clinical trials use risk-based quality management components. Lack of internal awareness is the top challenge to adoption.

## Why Download this Impact Report?

A study by Tufts, in collaboration with CluePoints and PwC, found that approximately half of clinical trials use risk-based quality management components on average to document, verify, and resolve study risks and deviations. The  majority of respondents trust that doing so improves clinical trial quality, increases efficiency, and speeds up timelines. 

Given the enthusiasm surrounding the use of RBQM in trials, the major barrier to its adoption seems to be a lack of internal and cross-functional awareness—which is common across small, medium, and large pharmaceutical and biotechnology companies and contract research organizations (CROs).

Download the case study to discover how Tufts CSDD conducted this research and evaluated the responses to determine why the adoption of RBQM remains limited. 

Got a question? Give us a call at +1 617 765 7129, or email [contact@cluepoints.com](mailto:contact@cluepoints.com) 

### First Pain Point

This should be the biggest pain your clients have as it relates to your service. What are you doing for them?

[Read More](https://www.webcanopystudio.com)

### First Pain Point

This should be the biggest pain your clients have as it relates to your service. What are you doing for them?

[Read More](https://www.webcanopystudio.com)

### First Pain Point

This should be the biggest pain your clients have as it relates to your service. What are you doing for them?

[Read More](https://www.webcanopystudio.com)

![prelude2logo-dark](https://cdn2.hubspot.net/hub/395201/hubfs/Prelude%202.0/prelude2logo-dark.png?width=3942&name=prelude2logo-dark.png "prelude2logo-dark")

© 2026 CluePoints Inc.

```json
{
  "@context" : "https://schema.org",
  "@type" : "EducationEvent",
  "about" : [ {
    "@type" : "Thing",
    "name" : "Risk-Based Quality Management (RBQM)"
  }, {
    "@type" : "Thing",
    "name" : "Clinical trial quality and efficiency"
  }, {
    "@type" : "Thing",
    "name" : "RBQM adoption barriers"
  }, {
    "@type" : "Thing",
    "name" : "Tufts Center for the Study of Drug Development (CSDD)"
  } ],
  "audience" : {
    "@type" : "Audience",
    "audienceType" : "Clinical operations professionals in pharmaceutical clinical trials"
  },
  "description" : "This case study from Tufts CSDD, developed with CluePoints and PwC, analyzes how often clinical trials use Risk-Based Quality Management (RBQM) and the impact on quality, efficiency and timelines. Discover why, despite strong confidence in RBQM, adoption remains limited due to internal and cross-functional awareness gaps across pharma, biotech and CROs.",
  "eventAttendanceMode" : "https://schema.org/OnlineEventAttendanceMode",
  "inLanguage" : "en-US",
  "isAccessibleForFree" : true,
  "location" : {
    "@type" : "VirtualLocation",
    "url" : "https://lp.cluepoints.com/hubfs/Tufts%20Impact%20Report.pdf"
  },
  "name" : "Tufts Center for the Study of Drug Development Impact Report: Analysis & Insight Into Critical Drug Development Issues",
  "organizer" : {
    "@type" : "Organization",
    "logo" : "https://cluepoints.com/wp-content/uploads/2024/03/clue_points_cmyk@2x.png",
    "name" : "CluePoints",
    "url" : "https://cluepoints.com/"
  },
  "potentialAction" : {
    "@type" : "DownloadAction",
    "target" : "https://lp.cluepoints.com/hubfs/Tufts%20Impact%20Report.pdf"
  },
  "url" : "https://lp.cluepoints.com/tufts-impact-report"
}
```